Case Details
- Case Title: Goh Seng Heng v RSP Investments & 6 Ors; and another matter
- Citation: [2016] SGHC 275
- Court: High Court of the Republic of Singapore
- Date of Decision: 12 December 2016
- Judges: Lai Siu Chiu SJ
- Proceedings: High Court — Suit No 546 of 2015 (Summons No 1124 of 2016) and Suit No 111 of 2016 (Summonses Nos 554, 754 and 934 of 2016)
- Applicant/Plaintiff in Suit No 546 of 2015: Goh Seng Heng (Dr Goh)
- Defendants/Respondents in Suit No 546 of 2015: RSP Investments and six others (including Terence Loh, Nelson Loh, Motcombe Holdings Limited, Justin Demetrio Reis, Peter Anthony Reis, and initially Lucy Wang Xiaopu)
- Plaintiffs in Suit No 111 of 2016: Aesthetic Medical Partners Pte Ltd; Aesthetic Medical Holdings Pte Ltd; PPP Investments Pte Ltd (added by leave)
- Defendants in Suit No 111 of 2016: Goh Seng Heng; Goh Ming Li Michelle (Wu Mingli); Quikglow Pte Ltd (formerly Dr Michelle Goh Pte Ltd); Lee Kin Yun; Koh Mui Lee; Goh Ming Yi Melissa
- Key Applications/Interlocutory Matters: (i) Dr Goh’s application for an injunction restraining shareholders from calling meetings to alter share capital (Summons No 1124 of 2016); (ii) Mareva injunction and asset disclosure (Summons No 754 of 2016); (iii) joinder application (Summons No 755 of 2016); (iv) AM group’s application for an injunction restraining competitive conduct and employment/engagement of Dr Goh and Michelle (Summons No 554 of 2016); (v) setting aside application targeting the Mareva injunction and the AM group’s injunction (Summons No 934 of 2016)
- Legal Areas: Civil Procedure; Injunctions; Mareva injunctions
- Judgment Length: 37 pages; 11,228 words
- Cases Cited: [2016] SGHC 275 (as provided in metadata)
Summary
This High Court decision arose from two interlinked suits involving a shareholder and investor dispute in a Singapore company operating aesthetic laser services and skincare-related products and services. The dispute was characterised as a “power struggle” between (on one side) Dr Goh Seng Heng and his family interests, and (on the other) a group of investors and entities associated with RSP Investments and related persons, as well as a separate but related set of claims brought by the company group against Dr Goh and his family for alleged breaches of fiduciary and contractual duties and for conspiracy.
In the first suit (Suit No 546 of 2015), Dr Goh sought an injunction to restrain the defendants from calling meetings for the purpose of altering the company’s share capital, including allotting or issuing shares and voting to alter share capital. The court dismissed Dr Goh’s application. In the second suit (Suit No 111 of 2016), the company group (the “AM group”) had obtained a Mareva injunction and related disclosure orders, and also obtained an injunction restraining competitive conduct. Dr Goh, Michelle and Quikglow applied to set aside those injunctions; the court dismissed the setting aside application.
Although the extracted text provided is truncated, the decision’s procedural posture is clear: the court was required to assess whether interlocutory injunctions—both restraining share-capital manoeuvres and restraining asset dissipation or competitive conduct—were justified on the evidence and on the applicable legal tests. The court’s reasoning reflects the Singapore approach to interlocutory relief, particularly the need to establish a serious question to be tried, a sufficient risk of irreparable harm or practical prejudice, and the appropriate balance of convenience, with heightened scrutiny for Mareva relief.
What Were the Facts of This Case?
The company at the centre of the dispute (incorporated in August 2008) owned and operated outlets in Singapore providing aesthetic laser services and skincare-related products and services. Dr Goh Seng Heng, a dermatologist by training, was the managing director and remained a shareholder. His daughters, Dr Michelle Goh and Dr Melissa Goh, were directors of the company, with Michelle also remaining a shareholder. Together with Dr Goh’s company, Dr Goh Seng Heng Pte Ltd, Dr Goh and Michelle held 13.31% of the shares.
RSP Investments, incorporated in the Cayman Islands, was a shareholder. RSP was controlled by Terence Loh and his cousin Nelson Loh. Motcombe Holdings Limited, a BVI company, had been a shareholder until 23 July 2014, and Motcombe was owned and/or controlled by Justin Demetrio Reis and his father Peter Anthony Reis. Another shareholder, Lucy Wang Xiaopu, was initially a defendant but was later removed when Dr Goh discontinued the action against her.
By the time of the dispute, the defendants and Lucy collectively held and/or controlled 63.47% of the shares. There were other shareholders besides Dr Goh, Michelle, Lucy and the six defendants. Importantly, 20 other shareholders controlling 20.88% of the shares agreed to vote as directed by Dr Goh and to grant him and Michelle the requisite proxies to vote their shares. This proxy arrangement was central to Dr Goh’s claim that he retained effective voting control despite losing majority shareholding status.
The factual genesis traced back to December 2013, when a fund called Lion Rock Capital (“Lion Rock”) wanted to invest in the company. Nelson, as a director of RSP, was tasked with structuring the deal. Dr Goh alleged that Nelson, without board approval, sought to arrange for Lion Rock to buy Nelson and Justin’s shares, which led to disagreements between Dr Goh, RSP and Justin.
On 24 January 2014, the parties entered into a settlement agreement (“the Settlement Agreement”) involving Dr Goh, the company, AMH, and GSHKML Pte Ltd (a company owned by Dr Goh and his family), as well as the defendants. Under the Settlement Agreement, Motcombe agreed to transfer 18,696 of its 62,319 shares to RSP (which already held 50,000 shares). RSP’s shareholding then increased further when it exercised an option to purchase additional shares granted to Justin, resulting in RSP owning 101,591 shares.
Crucially, the Settlement Agreement also provided that RSP, Terence and Nelson would appoint Dr Goh or Michelle as their proxies or representatives at all general meetings and would sign on their behalf all resolutions of shareholders passed by the company from time to time. Justin and Peter similarly agreed to appoint Dr Goh and Michelle as their proxies and representatives. Motcombe was to transfer its remaining shares to an individual acceptable to Dr Goh; Peter became that transferee in February 2014. Dr Goh later purchased shares from Peter, leaving Peter with 24,994 shares.
In late 2014, Dr Goh bought 18,679 shares from Peter. In addition, Dr Goh agreed to purchase 20,318 shares from RSP in the event of an IPO or trade sale. Dr Goh also entered into agreements with other shareholders (including Lucy) to ensure that he and/or Michelle would hold their voting rights as proxies, thereby preserving control notwithstanding the change in majority shareholding. Despite these arrangements, Dr Goh alleged that the defendants refused to provide executed proxy forms for an extraordinary general meeting scheduled for 9 June 2015 (“the June EGM”), despite letters from his solicitors. The defendants levelled accusations of wrongdoings and breaches of agreements against Dr Goh, which he denied.
Against this background, Dr Goh brought the 2015 Suit and sought an injunction (Summons No 1124 of 2016) to restrain the defendants from calling meetings for the purpose of altering share capital, including allotting or issuing shares and voting to alter share capital. He asserted that he and Michelle were in grave danger of being removed from the board if the defendants were not restrained, and that he sought only to preserve the status quo pending the outcome of his claim.
In the 2016 Suit, the AM group (the company and its wholly owned subsidiary AMH) sued Dr Goh, Michelle and Quikglow. Quikglow was incorporated by Dr Goh and Michelle on 5 March 2013 and was alleged to provide aesthetic medical treatment similar to and in competition with the PPP laser brand clinics operated by the AM group. The AM group’s pleaded causes of action included breaches of fiduciary and/or contractual duties and conspiracy by lawful and/or unlawful means.
The AM group obtained a Mareva injunction in Summons No 754 of 2016, restraining the defendants from disposing of their assets. An order dated 19 February 2016 restrained Dr Goh from disposing of his assets up to the value of $10m and required disclosure of assets in Singapore. The AM group also obtained leave to add PPP Investments as a third plaintiff and to join Lee, Koh Mui Lee and Melissa as defendants. Separately, the AM group obtained an injunction (Summons No 554 of 2016) restraining Dr Goh and Michelle from joining Quikglow and engaging in the same or similar business as the AM group, including restraining Quikglow from employing or engaging Dr Goh and Michelle’s services.
Dr Goh, Michelle and Quikglow then brought a setting aside application (Summons No 934 of 2016) seeking to set aside the Mareva injunction and the injunction granted in the AM group’s application. The court dismissed that setting aside application, and the defendants appealed.
What Were the Key Legal Issues?
The first cluster of issues concerned whether Dr Goh was entitled to interlocutory injunctive relief in the 2015 Suit to restrain the defendants from calling meetings intended to alter the company’s share capital. This required the court to consider the applicable injunction framework in Singapore: whether there was a serious question to be tried, whether damages would be an adequate remedy, and whether the balance of convenience favoured maintaining the status quo.
Because the relief sought in the 2015 Suit was directed at corporate governance actions (calling meetings and voting to alter share capital), the court also had to consider the practical consequences of granting or refusing the injunction. In particular, the court needed to assess whether the threatened actions would likely cause irreparable harm or render the eventual judgment nugatory, and whether the injunction would be proportionate to the risks identified.
The second cluster of issues concerned the propriety of Mareva relief and the setting aside of such relief in the 2016 Suit. Mareva injunctions are exceptional and require careful scrutiny. The court had to assess whether the AM group had met the heightened evidential threshold for Mareva relief, including demonstrating a real risk that the defendants would dissipate assets to frustrate enforcement of any judgment.
Finally, the court had to address the setting aside of the AM group’s injunction restraining competitive conduct and the engagement of Dr Goh and Michelle’s services. This required the court to consider whether the injunction was properly granted, whether the underlying claims disclosed a sufficient basis for interim protection, and whether the defendants had shown grounds to disturb the existing orders.
How Did the Court Analyse the Issues?
In relation to Dr Goh’s application in the 2015 Suit, the court’s analysis focused on the interlocutory injunction test and the evidential basis for the claimed urgency and risk. Dr Goh’s case was that he and Michelle faced grave danger of being removed from the board if the defendants called the June EGM or other meetings to alter share capital. The court accepted that the dispute involved control and governance, but interlocutory relief still required a careful assessment of whether the threatened corporate actions would cause harm that could not be adequately compensated by damages or otherwise addressed at trial.
The court also had to consider the nature of the relief sought: an injunction restraining the defendants from calling meetings for the purpose of altering share capital. Such relief is intrusive because it affects the defendants’ ability to exercise shareholder rights and to convene meetings. Accordingly, the court would have been expected to scrutinise whether the injunction was necessary to preserve the status quo and whether it was framed narrowly enough to address the alleged risk without overreaching.
Based on the court’s ultimate decision to dismiss Dr Goh’s application, the court likely concluded that the evidential foundation did not justify the breadth or immediacy of the restraint sought. Even where a serious question to be tried exists, the court may refuse an injunction if the balance of convenience does not favour granting it, or if the claimant has not shown that the harm is sufficiently likely and sufficiently irreparable. The court’s dismissal indicates that, on the evidence before it, the court was not persuaded that the threatened share-capital actions would cause the kind of practical prejudice that warranted the exceptional step of restraining corporate governance actions.
Turning to the 2016 Suit, the court’s approach to the Mareva injunction would have reflected the established Singapore principles governing such orders. Mareva relief requires the applicant to show, among other things, a good arguable case and a real risk of dissipation. The court also considers whether the order is proportionate and whether it is supported by evidence rather than speculation. The AM group had obtained an order restraining Dr Goh from disposing of assets up to $10m and requiring disclosure of assets in Singapore.
When Dr Goh, Michelle and Quikglow applied to set aside the Mareva injunction and the related disclosure order, the court would have assessed whether the defendants had demonstrated that the original order was wrongly made or that circumstances had changed. The dismissal of the setting aside application suggests that the court found the evidential basis for the Mareva injunction remained sound, and that the risk of dissipation or frustration of enforcement was sufficiently established. The court also would have considered that disclosure orders are often integral to Mareva relief, enabling the court and parties to understand the extent of assets and to calibrate the restraint.
Similarly, the court’s dismissal of the setting aside application insofar as it related to the AM group’s injunction indicates that the court was satisfied that the interim restraint was justified. In disputes involving alleged fiduciary breaches and competitive conduct, courts often consider whether interim protection is needed to prevent ongoing harm that cannot be adequately remedied by damages. The injunction granted in Summons No 554 of 2016 restrained Dr Goh and Michelle from joining Quikglow and from engaging in the same or similar business, including restraining Quikglow from employing or engaging their services. The court’s refusal to set aside implies that the AM group’s claims were sufficiently arguable and that the balance of convenience favoured maintaining the interim restraints pending trial.
Overall, the court’s reasoning reflects a consistent theme: interlocutory relief is not automatic. Even in a high-stakes shareholder dispute, the court requires a disciplined application of the injunction tests and a careful evaluation of evidence, proportionality, and practical consequences. The court’s willingness to maintain the Mareva and competitive injunctions, while refusing the shareholder-meeting injunction sought by Dr Goh, underscores that different forms of interim relief attract different levels of scrutiny and are granted only where the evidential and legal thresholds are met.
What Was the Outcome?
The court dismissed Dr Goh’s application in Summons No 1124 of 2016 in the 2015 Suit. As a result, the defendants were not restrained by the court from calling meetings for the purpose of considering and passing resolutions to alter share capital, including allotting or issuing shares and voting to alter share capital. Dr Goh filed a notice of appeal against that dismissal.
In the 2016 Suit, the court dismissed the setting aside application (Summons No 934 of 2016). The practical effect was that the Mareva injunction restraining Dr Goh from disposing of assets up to $10m, the asset disclosure order, and the injunction restraining competitive conduct remained in place pending the determination of the substantive claims. The defendants appealed the dismissal as well.
Why Does This Case Matter?
This case is significant for practitioners because it illustrates how Singapore courts manage complex, multi-party corporate disputes through interlocutory injunctions, while maintaining strict control over the evidential thresholds for different types of relief. Shareholder disputes often involve urgent attempts to preserve control or prevent dilution. However, the court’s dismissal of Dr Goh’s injunction application demonstrates that courts will not automatically grant restraints on corporate governance actions merely because a claimant alleges a risk to board composition or control.
For litigators, the decision also highlights the practical importance of evidence in Mareva applications and setting-aside proceedings. Mareva injunctions are powerful tools to prevent asset dissipation, but they are exceptional. The court’s refusal to set aside the Mareva and disclosure orders indicates that where the applicant provides sufficient evidence of risk and a good arguable case, the court will be reluctant to disturb the interim protection.
Finally, the case is useful for understanding how courts approach interim restraints in disputes involving alleged fiduciary breaches and competitive conduct. The maintenance of the injunction restraining competitive engagement suggests that, where there is a credible basis for claims and an ongoing risk of harm, interim orders may be justified even where the dispute is fact-intensive and involves overlapping corporate and personal relationships.
Legislation Referenced
- (Not provided in the supplied judgment extract.)
Cases Cited
- [2016] SGHC 275 (as provided in metadata)
Source Documents
This article analyses [2016] SGHC 275 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.